COMPARATIVE STUDY OF ORAL AND INTRALESIONAL VERAPAMIL IN PEYRONIE’S DISEASE
Journal Title: Journal of Evidence Based Medicine and Healthcare - Year 2017, Vol 4, Issue 38
Abstract
BACKGROUND Treatment of Peyronie's disease is a dilemma for the treating urologist. Part of this problem is due to an incomplete understanding of the aetiopathophysiology of the disease. Multiple nonsurgical treatment are available for Peyronie’s Disease (PD) including calcium channel blocker verapamil, both oral and intraplaque injectable. The use of verapamil is based on its capacity to alter fibroblast function and promote collagen degradation. As a result, calcium channel antagonists may have the capacity to slow, prevent or even reverse plaque formation. There are many studies suggesting benefits of intraplaque verapamil injection. In our study, we aim to compare the outcomes of oral versus intraplaque verapamil injection in terms of pain reduction, decrease in curvature and improved sexual function. MATERIALS AND METHODS In this randomised study, 20 patients were randomly divided into 2 groups of 10 patients each (Group I patients were treated with oral verapamil and group II patients were treated with intraplaque verapamil injection). Results from both the groups were compared and interpreted in terms of change in plaque size, curvature, erectile function and pain. Size of plaque was assessed with the help of color Doppler in pre and post-treatment period. All the 20 patients were followed for 3 years after completion of treatment. None of the 20 patients lost to follow up. RESULTS 30% of group I patients (oral verapamil) showed decreased plaque volume. Softening of plaque was noted in only 60% of the patients. Subjective erectile dysfunction improved in only 40% of the patients. In group, II patients who received intraplaque verapamil injection, 70% showed decreased plaque volume with improvement in penile curvature. There was softening of the plaque in all the patients in group II. Subjective erectile dysfunction improved in 60% of the patients. No local or systemic toxicity was noted except mild ecchymosis in 2 patients of group II. CONCLUSION This study concludes that intraplaque verapamil injection is more effective and reasonable option than oral verapamil in nonsurgical patients of Peyronie’s disease. Maximum benefits are seen up to 3 months of treatment.
Authors and Affiliations
Saju P. R, Vaibhav Vikas, Praveen Gopi, Rustum Singh Kaurav
Keywords
Related Articles
- EP ID EP219135
- DOI 10.18410/jebmh/2017/452
- Views 78
- Downloads 0
A PROSPECTIVE STUDY OF MODERATE TO SEVERE ANAEMIA IN ELDERLY HOSPITALISED PATIENTS IN A TERTIARY CARE CENTRE
BACKGROUND The prevalence of anaemia in elderly population is of great significance as it is a manifestation of the underlying disease and produces severe complications in the elderly. The etiopathogenesis of anaemia in...
OUTCOME OF RESULTS WITH CONSERVATIVE MANAGEMENT OF ROCKWOOD TYPE III ACROMIOCLAVICULAR DISLOCATION
BACKGROUND The acromioclavicular joint is commonly involved in traumatic injuries that affect the shoulder. Treatment of these injuries has been controversial and continues to evolve. The aim of the study is to evaluate...
CT ENTEROCLYSIS VERSUS CT ENTEROGRAPHY IN THE EVALUATION OF SUSPECTED SMALL BOWEL PATHOLOGIES - A CASE SERIES
BACKGROUND With the advent of computed tomography (CT), CT enterography has become the investigation of choice for evaluating small bowel disorders, as it allows better visualization of the bowel wall. As a result, CT en...
STUDY OF CLINICAL PROFILE AND DIFFERENTIATING SYSTOLIC AND DIASTOLIC HEART FAILURE BY ECHOCARDIOGRAPHY
BACKGROUND Heart failure is a complex clinical syndrome that results from any structural or functional impairment of ventricular filling or ejection of blood. The primary manifestation of heart failure is dyspnoea and fa...
STUDY OF CORONARY RISK FACTORS AMONG MIGRANT WORKERS IN MANGALORE CITY
BACKGROUND: Cardiovascular disease causes 29 per cent of all deaths globally each year, making it the world’s number one killer. Every year, 17.1 million lives are claimed by the global burden of cardiovascular disease....